Sichuan Kelun Pharmaceutical (002422.SZ): Xituximab N01 injection approved for market launch.

Sichuan Kelun Pharmaceutical (002422.SZ) announced that its subsidiary Sichuan Kelun Botai Biopharmaceutical Co., Ltd.'s recombinant epidermal growth factor receptor (EGFR) human-mouse chimeric monoclonal antibody - cetuximab injection (formerly known as A140) (Detelai) has been approved by China's National Medical Products Administration (NMPA) for listing in China. It is indicated for use in combination with FOLFOX or FOLFIRI regimens for first-line treatment of RAS wild-type metastatic colorectal cancer, at a dose of 500mg/m2 once every two weeks, or an initial dose of 400mg/m2 followed by a maintenance dose of 250mg/m2 once a week.